AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Rheo Clinic, a subsidiary of TLC Vision Corporation (TLCV), announced Institutional Review Board (IRB) approval and the official launch of patient enrollment in a new study called the Prospective Evaluation of Visual Functioning with Rheopheresis Treatment for Age-Related Macular Degeneration in Canada (PERC).
The PERC study's principal investigator is retinologist David Wong, MD, FRCSC. Co-investigators are Yoel Abells, MD; Sanjive Jain, MD; Kelly Wong, MD; and Lorne Langer, MD. The protocol was designed by Trefford Simpson, PhD.
PERC is a single center, prospective study designed to examine the effect of rheopheresis (RHEO) treatments on the outcome variables for 60 patients.
Each patient will receive a series of 8 RHEO treatments over a 10- to 12-week period. Clinical data will be collected at 3-month intervals for 1 year following the initial treatments.
One objective of the study is to develop a complete description of the physiological changes produced by RHEO therapy. This will be done using structural, functional, and ...
Source: HighBeam Research, Patient enrollment launched for age-related macular degeneration...